tbuckley/cabot-search huggingface dataset:
<i>Announcement:</i> National Child Passenger Safety Week — September 17–23, 2017
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

September marks Childhood Cancer Awareness Month.Each year, approximately 15,000 U.S. children and adolescents aged <20 years receive a cancer diagnosis; leukemia, brain tumors, and lymphoma are the most common types of cancers that affect this age group (1).During the past 4 decades, largely because of advances in the efficacy of treatment and supportive care, 5-year relative survival for childhood cancers increased from 62% to 85% (2).However, for some childhood cancers, such as brain or bone tumors, 5-year relative survival remains <75% (2).In addition, child and adolescent cancer survivors often face long-term complications, including heart disease, infertility, or secondary cancers related to their treatment, and need lifelong survivorship care planning (3).CDC addresses the needs of children and adolescents living with, through, and beyond cancer by collecting and analyzing data and using scientific knowledge to develop and implement interventions.CDC works with local, state, and national partners to address disparities in referral to, enrollment in, and availability of childhood cancer clinical trials.To strengthen cancer survivorship care for children and adolescents, CDC collaborates with partner agencies to research barriers to clinical trial enrollment and interventions to improve care planning and self-management after completion of cancer treatment.United States Cancer Statistics surveillance data (https:// nccd.cdc.gov/uscs/) are important for monitoring childhood cancer incidence and mortality.CDC's Pediatric and Young Adult Early Case Capture program (https://www.cdc.gov/cancer/npcr/early-case-capture.htm)specializes in rapid reporting of childhood cancer data, which can provide clinicians, researchers, and public health professionals with timely, relevant data.
January 9, 2002
Journal: JAMA (2002)

Xiaobin Wang, MD, MPH, ScD; Barry Zuckerman, MD; Colleen Pearson, BA; Gary Kaufman, MD; Changzhong Chen, MD; Guoying Wang, MD, PhD; Tianhua Niu, ScD; Paul H. Wise, MD, MPH; Howard Bauchner, MD; Xiping Xu, MD, PhD, MS
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia
Authors: Uday P. Kulkarni, Sushil Selvarajan, Sharon Lionel, Mithun A. Prakash, Hamenth Kumar Palani, Nithya Balasundaram, Arvind Venkataraman, Anu Korula, Anup J. Devasia, N. A. Fouzia, Nancy Beryl Janet, Sukesh Chandran Nair, Aby Abraham, Thenmozhi Mani, Jeyaseelan Lakshmanan, Arun Kumar Arunachalam, Poonkuzhali Balasubramanian, Biju George, Vikram Mathews
Journal: Blood Cancer Journal (2022)

Real world data with concurrent retinoic
Film Reviews
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Report of the Committee on Vaccination on an Anatomical Investigation into the Routes by Which Infections May Pass from the Nasal Cavities into the Brain.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Alcohol Withdrawal
Authors: Douglas W. Thomas
Journal: JAMA (1965)

<h3>To the Editor:—</h3> Dr. Gessner's proposal to treat delirium tremens on the model of barbiturate addiction is interesting and clinicians who to our knowledge have attempted such treatment should be encouraged to report even negative results. It is unfortunately true that we still lack sufficient basic information about the mechanisms underlying tolerance and their relationship to the development of delirium tremens. There are, however, practical and conceptual difficulties in using the barbiturate model to rationalize a treatment regimen, to explain the etiology of delirium tremens, or to construct an adequate test for severity of the disorder. Withdrawal from alcohol is, without doubt, a major, often necessary, but not sufficient etiological factor. The continued ingestion of alcohol produces direct toxic effects<sup>2,3</sup>as well as metabolic disturbances, which among other factors (including sleep deprivation) complicate the picture. Nor is the relation between amount and duration of alcohol ingestion and delirium tremens
Lexikon der gesamten Therapie des praktischen Arztes mit Einschluss der therapeutischen Technik.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma
Authors: Mrinal M. Gounder, Evan Rosenbaum, Nian Wu, Mark A. Dickson, Tahir N. Sheikh, Sandra P. D'Angelo, Ping Chi, Mary Lou Keohan, Joseph P. Erinjeri, Cristina R. Antonescu, Narasimhan Agaram, Meera R. Hameed, Moriah Martindale, Robert A. Lefkowitz, Aimee M. Crago, Sam Singer, William D. Tap, Naoko Takebe, Li-Xuan Qin, Gary K. Schwartz
Journal: Clinical Cancer Research (2022)

Abstract Purpose: Because the Hedgehog and Notch pathways are often overexpressed in mesenchymal malignancies, we evaluated the efficacy of concurrent inhibition of Notch and Hedgehog signaling using the gamma-secretase inhibitor (GSI) RO4929097 and the smoothened antagonist vismodegib in unresectable or metastatic sarcoma. Patients and Methods: In this investigator-initiated trial, phase Ib used standard 3+3 dose escalation in which patients first received vismodegib once daily for 21 days, followed by the combination of RO4929097 concurrently with vismodegib in 21-day cycles. In phase II, patients were randomized to RO4929097 alone or in combination with vismodegib. Results: Nine patients were treated in phase Ib with no dose-limiting toxicities. RO4929097 at 15 mg daily in combination with 150 mg daily of vismodegib was declared the recommended phase II dose. Most adverse events were grade ≤ 2. In phase II (closed early due to discontinuation of RO4929097 evaluation), 34 patients were randomized to RO4929097 alone and 33 to RO4929097 plus vismodegib. RO4929097 did not interfere with the steady-state concentration of vismodegib, while vismodegib reduced the plasma concentration of RO492909. No patients had an objective response. Neither progression-free nor overall survival differed significantly between treatment arms. Paired tumor biopsies from a subset of patients demonstrated inhibition of cleaved Notch. Conclusions: The combination of RO4929097 plus vismodegib was generally well tolerated. Although accrual to this study was not completed, vismodegib did not meaningfully enhance the clinical efficacy of RO4929097 in an unplanned analysis. GSIs and GSIs plus vismodegib can inhibit intratumoral Notch and downstream phosphorylated Akt signaling.
<scp>COVID</scp>‐19 vaccines and risks of hematological abnormalities: Nested case–control and self‐controlled case series study
Authors: Chor‐Wing Sing, Casey Tze Lam Tang, Celine Sze Ling Chui, Min Fan, Francisco Tsz Tsun Lai, Xue Li, Eric Yuk Fai Wan, Carlos King Ho Wong, Esther Wai Yin Chan, Ivan Fan Ngai Hung, Anskar Yu‐Hung Leung, Ching‐Lung Cheung, Ian Chi Kei Wong
Journal: American Journal of Hematology (2022)

Abstract Several studies reported hematological abnormalities after vaccination against the coronavirus disease 2019 (COVID‐19). We evaluated the association between COVID‐19 vaccines (CoronaVac and BNT162b2) and hematological abnormalities. We conducted nested case–control and self‐controlled case series analyses using the data from the Hong Kong Hospital Authority and the Department of Health, HKSAR. Outcomes of interest were thrombocytopenia, leukopenia, and neutropenia. Adjusted odds ratios (aORs), incidence rate ratios (IRRs), and 95% confidence intervals (CIs) were estimated using conditional logistic regression. In total, 1 643 419 people received COVID‐19 vaccination (738 609 CoronaVac; 904 810 BNT162b2). We identified 457 and 422 cases after CoronaVac and BNT162b2 vaccination, respectively. For CoronaVac, the incidence of thrombocytopenia, leukopenia, and neutropenia was 2.51, 1.08, and 0.15 per 10 000 doses. For BNT162b2, the corresponding incidence was 1.39, 1.17, and 0.26 per 10 000 doses. The incidence per 10 000 COVID‐19 cases were 1254, 2341, and 884, respectively. We only observed an increased risk of leukopenia following the second dose of BNT162b2 (aOR 1.58, 95% CI 1.24–2.02; day 0–14, IRR 2.21; 95% CI 1.59–3.08). There was no increased risk of any hematological abnormalities after CoronaVac vaccination. We observed an increased risk of leukopenia shortly after the second dose of BNT162b2. However, the incidence was much lower than the incidence following severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections. There was no association between CoronaVac and hematological abnormalities. The benefits of vaccination against COVID‐19 still outweigh the risk of hematological abnormalities.
Identification of Mitochondrial DNA Variants Associated With Risk of Neuroblastoma
Authors: Xiao Chang, Yichuan Liu, Joseph Glessner, Cuiping Hou, Huiqi Qu, Kenny Nguyen, Patrick Sleiman, Lobin Lee, Sharon J Diskin, John M Maris, Hakon Hakonarson
Journal: JNCI Journal of the National Cancer Institute (2022)

Neuroblastoma is a childhood cancer that originates in the developing sympathetic nervous system. We previously reported a crucial role of mitochondrial DNA haplogroups in the pathology of neuroblastoma. To pinpoint mitochondrial DNA variants associated with neuroblastoma risk, we applied a mitochondrial genome imputation pipeline to the single nucleotide polymorphisms array data of 2 pediatric cohorts containing a total of 2404 neuroblastoma patients and 9310 cancer-free controls. All statistical tests were 2-sided. The single nucleotide variant, rs2853493, was statistically significantly associated with neuroblastoma risk in the discovery cohort (odds ratio = 0.62, 95% confidence interval = 0.53 to 0.72, P < .001) and further confirmed in the replication cohort (odds ratio = 0.75, 95% confidence interval = 0.62 to 0.90, P = .002). Further, expression quantitative trait loci analysis indicated genotypes of rs2853493 were associated with expression levels of MT-CYB gene expression in neuroblastoma cells, suggesting rs2853493 may confer risk to neuroblastoma via regulating the expression level of its nearby genes.
TCT-188 Safety and Clinical Performance of the Drug-Eluting Absorbable Metal Scaffold in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries at 36-Month Follow-Up: BIOSOLVE-II and BIOSOLVE-III
Authors: Michael Haude, Hüseyin Ince, Stephan Kische, Alexandre Abizaid, Ralph Toelg, Pedro A. Lemos, Nicolas Van Mieghem, Stefan Verheye, Clemens von Birgelen, Evald Christiansen, Franz-Josef Neumann, Bernhard Witzenbichler, Christoph Kaiser, Eric Eeckhout, Javier Escaned, Hector Garcia-Garcia, Ron Waksman
Journal: Journal of the American College of Cardiology (2019)
The coexistence of asthma and COPD: some considerations about prevalence and lung function decline
Authors: Alessandro Marcon, Francesca Locatelli, Simone Accordini
Journal: European Respiratory Journal (2022)

With great interest we read the editorial by Mannino [1] regarding the investigation on the coexistence between asthma and COPD that we conducted using data from the population-based European Community Respiratory Health Survey (ECRHS) [2]. Mounting evidence suggests that FEV1 decline is slower among patients with COPD and asthma compared to those with COPD alone <https://bit.ly/33NyoJq>
JCC: Falling standards and dangers to patients
Journal: BMJ (1977)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following JCC: Falling standards and dangers to patients Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Knowledge of Early Peanut Introduction Guidelines Among Parents of Patients in a General Pediatric Clinic in an Inner-City Hospital
Authors: Sumeet Sandhu, Monique Hanono, Sonia Gandhi, Lawrence Hanson, Yana Kryvokhyzha, Ghanavi Kumaran, Carly Rabin, Rob Harriz, Martin Caha, Sairaman Nagarajan, Maria-Anna Vastardi
Journal: Journal of Allergy and Clinical Immunology (2022)
P42.03 Predictive Factors of Response to PD-(L)1 Inhibitors in Patients With Advanced Non-Small Cell Lung and High PD-L1 Expression
Authors: A. Barba Joaquín, J. Mosquera, M. Riudavets Melià, M.I. Gomez-Randulfe, M.R. García Campelo, I. Sullivan, J. Serra Lopez, M. Aguado, A. Piedra, M. Majem
Journal: Journal of Thoracic Oncology (2021)
Dynamic 3D genome architecture of cotton fiber reveals subgenome-coordinated chromatin topology for 4-staged single-cell differentiation
Authors: Liuling Pei, Xianhui Huang, Zhenping Liu, Xuehan Tian, Jiaqi You, Jianying Li, David D. Fang, Keith Lindsey, Longfu Zhu, Xianlong Zhang, Maojun Wang
Journal: Genome biology (2022)

Despite remarkable advances in our knowledge of epigenetically mediated transcriptional programming of cell differentiation in plants, little is known about chromatin topology and its functional implications in this process.
Introducing MEDWatch
Authors: David A. Kessler
Journal: JAMA (1993)

UNFORTUNATELY, many health professionals do not think to report adverse events that might be associated with medications or devices to the Food and Drug Administration (FDA) or to the manufacturer. That needs to change, and the FDA is taking steps to encourage that to happen. Reports from health professionals of adverse events or product quality problems are essential to ensure the safety of drugs, biologicals, medical devices, and other products regulated by the FDA once they are introduced into the US market. Even the large, well-designed clinical trials that are conducted to gain pre-market approval cannot uncover every problem that can come to light once a product is widely used. A new drug application, for example, typically includes safety data on several hundred to several thousand patients. If an adverse event occurs in perhaps one in 5000 or even one in 1000 users, it could be missed in clinical trials
Praxis der Pneumologie, Stuttgart
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
Authors: Sarah Anne Bird, David Cairns, Faith E. Davies, Kevin Boyd, Gordon Cook, Mark T Drayson, Walter M Gregory, Matthew Jenner, John R Jones, Martin F. Kaiser, Roger G. Owen, Nigel H. Russell, Gareth Morgan, Graham Jackson, Charlotte Pawlyn
Journal: Blood (2019)
lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth
Authors: Haobo Li, Lena E. Trager, Xiaojun Liu, Margaret H. Hastings, Chunyang Xiao, Justin Guerra, Samantha To, Guoping Li, Ashish Yeri, Rodosthenis Rodosthenous, Michael G. Silverman, Saumya Das, Amrut V. Ambardekar, Michael R. Bristow, Juan Manuel González-Rosa, Anthony Rosenzweig
Journal: Circulation (2022)

The heart grows in response to pathological and physiological stimuli. The former often precedes cardiomyocyte loss and heart failure; the latter paradoxically protects the heart and enhances cardiomyogenesis. The mechanisms underlying these differences remain incompletely understood. Although long noncoding RNAs (lncRNAs) are important in cardiac development and disease, less is known about their roles in physiological hypertrophy or cardiomyogenesis.RNA sequencing was applied to hearts from mice after 8 weeks of voluntary exercise-induced physiological hypertrophy and cardiomyogenesis or transverse aortic constriction for 2 or 8 weeks to induce pathological hypertrophy or heart failure. The top lncRNA candidate was overexpressed in hearts with adeno-associated virus vectors and inhibited with antisense locked nucleic acid-GapmeRs to examine its function. Downstream effectors were identified through promoter analyses and binding assays. The functional roles of a novel downstream effector, dachsous cadherin-related 2 (DCHS2), were examined through transgenic overexpression in zebrafish and cardiac-specific deletion in Cas9-knockin mice.We identified exercise-regulated cardiac lncRNAs, called lncExACTs. lncExACT1 was evolutionarily conserved and decreased in exercised hearts but increased in human and experimental heart failure. Cardiac lncExACT1 overexpression caused pathological hypertrophy and heart failure; lncExACT1 inhibition induced physiological hypertrophy and cardiomyogenesis, protecting against cardiac fibrosis and dysfunction. lncExACT1 functioned by regulating microRNA-222, calcineurin signaling, and Hippo/Yap1 signaling through DCHS2. Cardiomyocyte DCHS2 overexpression in zebrafish induced pathological hypertrophy and impaired cardiac regeneration, promoting scarring after injury. In contrast, murine DCHS2 deletion induced physiological hypertrophy and promoted cardiomyogenesis.These studies identify lncExACT1-DCHS2 as a novel pathway regulating cardiac hypertrophy and cardiomyogenesis. lncExACT1-DCHS2 acts as a master switch toggling the heart between physiological and pathological growth to determine functional outcomes, providing a potentially tractable therapeutic target for harnessing the beneficial effects of exercise.
Dissociative Anesthesia
Authors: John W. Pender
Journal: JAMA (1971)

Dissociative anesthesia is a different type of anesthesia, characterized in the patient by catalepsy, amnesia, and marked analgesia. The clinical effects on the central nervous and cardiovascular systems of patients are so different from those of conventional anesthesia, produced with barbiturates and hydrocarbons, that reorientation of the reflexes of the anesthesiologist is necessary for most effective use. Dissociative anesthesia still is in the process of being perfected.
Setting maternal mortality targets for the SDGs
Authors: Amy Boldosser-Boesch, Michel Brun, Liliana Carvajal, Doris Chou, Luc de Bernis, Karen Fogg, Kathleen Hill, Rima Jolivet, Betsy McCallon, Allisyn Moran, Lale Say, Jeffrey Smith, Mary E Stanton, Petra ten Hoope-Bender, Mary N Wegner
Journal: The Lancet (2017)